Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. (NAUT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
naut · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$2.50
Consensus
$2.50
+7.3% upside
Low
$2.50
Median: $2.5 · Last Close: $2.33
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.29 | ↓ 1.80% |
1-day model range: $2.27–$2.31. Peak: $2.31 (-1.80%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -38.0% |
| 2028 | $1 | -49.8% |
| 2029 | $1 | -54.5% |
| 2030 | $1 | -56.7% |
| 2031 | — | -57.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NAUT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-02-27 | Guggenheim | Maintains | Buy→Buy |
| 2024-12-05 | Goldman Sachs | Downgrade ↓ | Neutral→Sell |
| 2023-08-03 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2022-08-03 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2022-08-03 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2022-07-14 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2022-04-13 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2022-01-06 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2021-11-02 | Cowen & Co. | Maintains | Outperform→Outperform |
| 2021-08-04 | Goldman Sachs | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Nautilus Biotechnology, Inc. (NAUT) stock. Of the recent 11 rating actions, 0 were upgrades and 1 were downgrades. 5 analysts currently cover NAUT.
Analyst Recommendation Trends
NAUT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 97.7% YoY
Revenue Next Year
$8M
↑ 992.9% YoY
EPS This Year
$-0.52
EPS Next Year
$-0.52
↑ 1.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast NAUT EPS of $-0.52 for the current fiscal year, based on estimates from 2 analysts. The NAUT revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NAUT stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NAUT price target is $2.50 (+7.3% upside), with an analyst consensus of Buy.
The NAUT short-term stock prediction for tomorrow is $2.29 (-1.80%). The NAUT stock price prediction for 2027 estimates an average of $1. The NAUT stock prediction for 2030 projects a range of $1–$1.
Nautilus Biotechnology, Inc. trades on NASDAQ under the ticker NAUT. The NAUT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.
Frequently asked questions
NAUT forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month NAUT price target is $2.50, with a high forecast of $2.50 and a low of $2.50. The median price target is shown in the chart above when available. This implies +7.3% potential upside from the current price of $2.33.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.